Physician profile
William E Barnes
NPI 1457821340
$3,859.01
in general payments reported to CMS, 2019-2025
11 companies · $3,859 in 2025
The $3,859 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119 · Consulting Fee: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.01 |
| Consulting Fee | $740.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $771.89 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $540.77 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $485.28 | 2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $459.54 | 2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $442.05 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $348.47 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $343.48 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $242.94 | 2025 | Aristada, Lybalvi |
| Abbvie INC. | $99.89 | 2025 | |
| Axsome Therapeutics, INC. | $94.27 | 2025 | Auvelity |
| Lundbeck LLC | $30.43 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.